Why Canada? Canada has a rich ecosystem for biomanufacturing R&D and investment. It has specific strengths in RNA production, cell and gene therapy, regenerative medicine, and related delivery systems. With world-class academics, many R&D intensive SMEs, and clinical trial and manufacturing infrastructure, it is an ideal collaboration partner for the UK.
This programme is particularly relevant for businesses developing innovative technologies that enable the development and manufacture of novel biological therapeutic products and delivery systems, including, but not limited to:
- vaccines (prophylactic, therapeutic, various platforms)
- therapeutic proteins
- advanced therapy medicinal products, including messenger RNA, small interfering RNA, gene therapies, cell therapies, engineered tissues
- other biological based therapies, such as bacteriophage or engineered probiotics
- viral and non-viral, for example Lipid Nano Particles (LNP) platforms, including their components and payloads, as delivery systems for proteins and nucleic acids
Find out how our GBIP in Canada can help your business grow.
Follow this link to complete and submit your application.
Download a copy of the application form so you can prepare your answers in advance.
- Closing date for application: Wednesday 13th September 2023 at 5pm
- Two-day pre-visit workshop: 12th – 13th October 2023
- Innovation visit: Sunday 12th – Saturday 18th November 2023
- Exploitation workshop: Tuesday 16th January